Hybrid liver support systems (LSS) for the use of pig liver cells are under development for extracorporeal therapy of acute liver failure and for bridging to liver transplantation. A literature overview about possible immunological side effects of a clinical application is given. The data summarised from experimental studies and those clinical applications of porcine cells reported so far, suggest that clinical use of LSS utilising porcine cells and an immuno-isolation membrane should not be compromised by severe immunological complications. The reported data suggest that clinical application should be conducted in conjunction with carefully planned immunological monitoring. Only after such applications of LSS have been carried out and further data have been evaluated, might one be able to judge the immunological consequences of broader application of hybrid liver support.
NybergS.L., ShatfordR.A., HuW.S., PayneW.D., CerraF.B.. Hepatocyte culture systems for artificial liver support: implications for critical care medicine.Crit Care Med1992; 20: 1157–68.
2.
GerlachJ., ZiemerR., NeuhausP.. Fulminant liver failure: relevance of extracorporeal hybrid liver support systems.Int J Artif Organs1996; 19: 7–13.
3.
GerlachJ., EnckeJ., HoleO., MüllerC., RyanC.J., NeuhausP.. Bioreactor for larger scale hepatocyte in vitro perfusion.Trans-plantation1994; 58: 984–8.
4.
GerlachJ., SchnoyN., EnckeJ., MüllerC., SmithM., NeuhausP.. Electron microscopic studies on a hepatocyte culture model with woven multicompartment capillary systems.Hepatology1995; 22: 546–52.
5.
GerlachJ., BrombacherJ., KlöppelK., SchnoyN., NeuhausP.. Comparison of four methods for mass hepatocyte isolation from pig and human livers.Transplantation1994; 57: 1318–22.
6.
RozgaJ., WilliamsF., RoM.S.. Development of a bioartificial liver: properties and function of a hollow-fiber module inoculated with liver cells.Hepatology1993; 17: 258–65.
7.
GerlachJ., EnckeJ., HoleO., MüllerC., CourtneyJ., NeuhausP.. Hepatocyte culture between three dimensional arranged biomatrix-coated independent artificial capillary systems and sinusoidal endothelial cell co-culture compartments.Int J Artif Organs1994; 17: 301–6.
8.
CheungA.K., HendersonL.W.. Effects of complement activation by hemodialysis membranes.Am J Nephrol1986; 6: 81–91.
9.
ShaldonS., VienkenJ.. Biocompatibility: is it a relevant consideration for today's haemodialysis?Int J Artif Organs1996; 19: 201–14.
10.
GerlachJ., JörresA., TrostO.. Side effects of hybrid liver support therapy: TNF-alpha liberation in pigs, associated with extracorporeal bioreactors.Int J Artif Organs1993; 16: 604–8.
11.
PlattJ.L., FischelR.J., MatasA.J., ReifA., BolmanM., BachF.H.. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model.Transplantation1991; 52: 214.
12.
McCurryK.R., KooymanD.L., AlvaradoC.G.. Human complement regulatory proteins protect swine-to-primate cardiac xenograft from humoral injury.Nature Medicine1995; 1: 423–7.
13.
StevensR.B., PlattJ.L.. The pathogenesis of hyperacute xenograft rejection.Am J Kidney Dis1992; 20: 414–21.
14.
SoaresM., HavauxX., Van BenedenR.. Characterisation of rat anti-guinea pig circulating xenoreactive natural antibodies and secreting cells.Transplant Proc1995; 27: 282–5.
15.
CotterellA.H., CollinsBH, ParkerW, HarlandRC, PlattJL. The humoral immune response in humans following cross-perfusion of porcine organs.Transplantation1995; 60: 861–8.
16.
GaliliU., TibellA., SamuelssonB., RydbergL., GrothC.G.. Increased anti-Gal activity in diabetic patients transplanted with fetal porcine islet cell clusters.Transplantation1995; 59: 1549–56.
17.
LaVecchioJ.A., DunneA.D., EdgeA.S.B.. Enzymatic removal of alpha-galactosyl epitopes from porcine endothelial cells diminishes the cytotoxic effect of natural antibodies.Transplantation1995; 60: 841–7.
18.
VaughanH.A., McKenzieI.F.C., SandrinM.S.. Biochemical studies of pig xenoantigens detected by naturally occurring human antibodies and the Galactose-alpha (1,3) Galactose reactive lectin.Transplantation1995; 59: 102–9.
19.
ParkerW., BrunoD., HolzknechtZ.E., PlattJ.L.. Characterization and affinity isolation of xenoreactive human natural antibodies.J Immunol1994; 153: 3791–803.
20.
GaliliU., KobrinE., ShohetS.B., StultsC.L.M., MacherB.A.. Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells.J Biol Chem1988; 263: 17755.
21.
GaliliU., AnarakiF., ThallA., Hill-BlackC., RadicM.. One percent of circulating B lymphocytes are capable of producing the natural anti-Gal-antibody.Blood1993; 82: 2485.
22.
KujundzicM., KorenE., NeethlingF.A.. Variability of anti-alpha-Gal antibodies in human serum and their relation to serum cytotoxicity against pig cells.Xenotransplantation1994; 1: 58–65.
23.
SchaapherderA.F., GooszenH.G., te BulteM.T., DahaM.R.. Human complement activation via the alternative pathway on porcine endothelium initiated by IgA antibodies.Transplantation1995; 60: 287–91.
24.
VaughanH.A., LovelandB.E., SandrinM.S.. GAL-alpha (1,3) GAL is the major xenoepitope expressed on pig endothelial cells recognised by naturally occurring cytotoxic human antibodies.Transplantation1994; 58: 879–82.
25.
GaliliU., MandrellR.E., HamahdehR.M., ShohetS.B., GriffisJ.M.. Interaction between human natural anti-alpha-galactosyl immunoglobilin G and bacteria of the human flora.Infect Immun1988; 56: 1730.
26.
GoldbergL., LeeJ., CairnsT.. Inhibition of the human antipig xenograft reaction with soluble oligosaccharides.Transplant Proc1995; 27: 249–50.
27.
LarsenR.D., Rivera-MarreroC.A., ErnstL.K., CummingsR.D., LoweJ.D.. Frame-shift and nonsense mutations in a human genomic sequence homologous to a murine UDP-GALß-DGAL (1,4)-D-Glc-NAc-alpha (1,3) Galactosyltransferase cDNA.J Biol Chem1990; 265: 7055.
28.
McKenzieI.F.C., KoulmandaM., MandelT., XingP-X, SandrinM.S.. Comparative studies of the major xenoantigen GAL-alpha (1,3) gal in pigs and mice.Transplant Proc1995; 27: 247–8.
29.
PlattJ.L., HolzknechtZ.E.. Porcine platelet antigens recognized by human xenoreactive natural antibodies.Transplantation1994; 57: 327–35.
30.
OriolR., YeY., KorenE., CooperD.K.C.. Carbohydrate antigens of pig tissues reacting with human natural antibodies as potential targets for hyperacute vascular rejection in pig-toman organ xenotransplantation.Transplantation1993; 56: 1433–42.
31.
CotterellA.H., AlvaradoC.G., LoganJ.S., PlattJ.L.. Variation in expression of porcine antigens recognized by human xenoreactive natural antibodies.Transplant Proc1995; 27: 278–9.
32.
AlvaradoC.G., CotterellA.H., McCurryK.R.. Variation in the level of xenoantigen expression in porcine organs.Transplantation1995; 59: 1589–96.
33.
MakowkaL., WuG.D., HoffmanA.. Immunohistopathologic lesions associated with the rejection of a pig-to-human liver xenograft.Transplant Proc1994; 26: 1074–5.
34.
RoittI.M.. Leitfaden der Immunologie.Blackwell4th ed., Berlin1993.
35.
FodorW.L., WilliamsB.L., MatisL.A.. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection.Proc Natl Acad Sci USA1994; 91: 11153–7.
36.
TectorA.J., EliasN., RosenbergL., SonderlandC., DuguidW.P., TehervenkowJ.L.. Why are pig livers perfused with the blood of patients in liver failure resistant to hyperacute rejection?Am Soc Transplant Surgeons. 22nd Annual Scientific Meeting, nn 5/29-31:1996; 127.
37.
LanzaR.P., KuhtreiberW.M., EckerD., StarukJ.E., ChickW.L.. Xenotransplantation of porcine and bovine islets without immunosuppression using uncoated alginate microspheres.Transplantation1995; 59: 1377–84.
LanzaR.P., BeyerA.M., StarukJ.E., ChickW.L.. Biohybrid artificial pancreas. Long-term function of discordant islet xenografts in streptozotocin diabetic rats.Transplantation1993; 56: 1067–72.
40.
de RidderM., DienemannD., DißmannW.. Zwei Todesfälle nach Zelltherapie.DMW1987; 112: 1006–9.
41.
ArchettiI.L., CapucciL., SaalmullerA., VerardiR., KonigM., AmadoriM.. Production and characterization of monoclonal antibodies differentiating subpopulations of porcine B lymphocytes in blood and lymphoid tissues.Zentralbl Veterinärmed1993; 40: 485–93.
42.
BianchiA.T., Moonen-LeusenH.W., van der HeijdenP.J., BokhoutB.A.. The use of a double antibody sandwich ELISA and monoclonal antibodies for the assessment of porcine IgM, IgG and IgA concentrations.Vet Immunol Immunopathol1995; 44: 309–17.
43.
TriulziD.J., JochumE.A., MarinoI.R., StarzlT.E.. Heteroagglutinins and their significance in baboon hepatic xenotransplantation.Transplantation1995; 60: 127–31.
44.
AbounaG.M., SerrouB., BoehmigH.G., AmemiyaH., MartineauG.. Long-term hepatic support by intermittent multi-species liver perfusions.Lancet1970; i: 391–6.
45.
LanzaR.P., BeyerA.M., ChickW.L.. Xenogenic humoral responses to islets transplanted in biohybrid diffusion chambers.Transplantation1994; 57: 1371–5.
46.
ColagiuriS., DellitS.. Suspected allergy to insulin preparations.Diabetes Care1988; 11: 365–6.
47.
YeY., LuoK., KobayashiT.. Secondary organ allografting after a primary “bridging” xenotransplant.Transplantation1995; 60: 19–22.
48.
EisemanB., LiemD.S., RafucciF.. Heterologous liver perfusion in treatment of hepatic failure.Ann Surg1965; 162: 329–36.
49.
OzawaK., KamiyamaY., KimuraK.. Clinical experience of postoperative hepatic failure treatment with pig or baboon liver cross-hemodialysis with an interposed membrane.Artif Organs1982; 6: 433–46.
50.
ChariR.S., CollinsB.H., MageeJ.C.. Treatment of hepatic failure with ex vivo pig-liver perfusion followed by liver transplantation.N Engl J Med1994; 331: 234–7.
51.
MargulisM.S., ErukhimovE.A., AndreimanL.A.. Temporary organ substitution by hemoperfusion through suspension of active donor hepatocytes in a total complex of intensive therapy in patients with acute hepatic insufficiency.Resuscitation1989; 18: 85–94.
52.
MargulisM.S., ErukhimovE.A., AndreimanL.A.. Hemoperfusion through suspension of cryopreserved hepatocytes in a treatment of patients with acute liver failure.Research in Surgery1990; 2: 99–102.
53.
RozgaJ., PodestaL., LePageE.. A bioartificial liver to treat severe acute liver failure.Ann Surg1994; 219: 538–46.
54.
TakahashiM., IshikuraH., TakahashiC., NakajimaY., MatsushitaM., MatsueH.. Immunologic considerations in the use of cultured porcine hepatocytes as a hybrid artificial liver.ASAIO J1993; 39: 242–6.
